Lunai Bioworks (LNAI) Non-Current Debt (2012 - 2025)

Lunai Bioworks (LNAI) posted quarterly Non-Current Debt of $1.3 million for Q4 2025, up 20.38% quarter-over-quarter from $1.0 million in Q3 2025.

Lunai Bioworks (LNAI) Non-Current Debt (2012 - 2025) Analysis & Trends

Lunai Bioworks' Non-Current Debt history runs 5 years deep, the most recent figure standing at $1.3 million for Q4 2025.

In Q4 2025, Non-Current Debt changed N/A year-over-year to $1.3 million; the TTM figure through Dec 2025 stood at $1.3 million (changed N/A YoY), while the FY2025 annual figure was $3.6 million, changed N/A from the prior year.
Non-Current Debt for Q4 2025 stood at $1.3 million, up from $1.0 million in the prior quarter.
The five-year high for Non-Current Debt was $4.7 million in Q3 2021, with the low at $1.0 million in Q3 2025.
The 3-year median for Non-Current Debt is $4.5 million (2021), against an average of $3.6 million.
Peak annual rise in Non-Current Debt reached 0.03% in 2021, while the deepest fall reached 0.04% in 2021.
Lunai Bioworks' Non-Current Debt stood at $4.7 million in 2021, then decreased by 0.03% to $4.7 million in 2022, then slumped by 73.13% to $1.3 million in 2025.
Business Quant data shows LNAI's Non-Current Debt at $1.3 million in Q4 2025, $1.0 million in Q3 2025, and $3.6 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	882.16 Mn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	-
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	546.77 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	8.96 Bn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	360.97 Mn
10	Lunai Bioworks	6.87 Mn	3.72 Mn	20,942.00	-

Download Data